: The hypothesis of this experiment is that with an increase of the chemokine CCL21, those who have had a lung transplant will have an increase in the overall survival rate. This process would occur by increasing the immune response to recognize a new organ as “normal” instead of foreign and dangerous. The specific aim of this study targets to reduce the rejection in post lung transplant subjects by increasing the amount of CCL21 by injecting the DC/CCL21 vaccination to express T and B cells more efficiently. Mice would be injected with an IPF (Idiopathic Pulmonary Fibrosis) cell line to have degenerative lungs, which will be removed and replaced with healthy lungs via a matching donor thus then the vaccine, DC/CCL21, will be injected to suppress the rejection rate. This new therapeutic approach would be implicated on the modeled organism mice to see the effects on the immune response, and hopefully be administered to humans in the near future if results are acceptable (Melero et al 2014).
Elliott, Cecilie, "CCL21 Protein Leads to Advancements in Understanding Lung Transplant Rejection" (2019). Spring Showcase for Research and Creative Inquiry. 32.